Type 2 Diabetes

all catalysts(0)

nothing on the calendar yet

News(10)

• Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
  Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.
  biospace · 1d ago
• STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
  Eli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide
  stat · 8d ago
• Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths
  Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths, a new study finds.
  stat · 8d ago
• Abbott teams with Google Health on AI-powered health insights app
  Two giants of their respective fields, Abbott and Google, are joining forces for a first-of-its-kind team-up that aims to build out a digital picture of people’s health.
  fiercebiotech · 9d ago
• Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetes
  Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
  raps · 10d ago
• Lilly climbs, Novo falls as obesity drug battle intensifies
  A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.
  biopharma_dive · 14d ago
• Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
  Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future bus…
  biospace · 15d ago
• ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
  Novo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigati…
  fiercebiotech · 15d ago
• Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
  Novo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…
  fiercebiotech · 15d ago
• Amgen drops early-stage obesity drug, upping pressure on MariTide
  Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight loss market onto the shoulders of phase 3 candidate MariTide.
  fiercebiotech · 16d ago